AngioDynamics (NASDAQ:ANGO) Updates FY25 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided EPS guidance of ($0.38)-($0.34) for the period, compared to the consensus EPS estimate of ($0.40). The company issued revenue guidance of $282-288 million, compared to the consensus revenue estimate of $283.86 million. AngioDynamics also updated its FY 2025 guidance to -0.380–0.340 EPS.

Wall Street Analyst Weigh In

ANGO has been the subject of a number of recent research reports. Canaccord Genuity Group lowered their price objective on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, October 4th. HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of AngioDynamics in a research report on Tuesday, December 10th.

AngioDynamics Price Performance

Shares of ANGO stock opened at $9.40 on Wednesday. AngioDynamics has a 12-month low of $5.26 and a 12-month high of $9.63. The firm has a market capitalization of $381.96 million, a price-to-earnings ratio of -1.54 and a beta of 0.59. The business has a 50 day simple moving average of $7.82 and a 200 day simple moving average of $7.27.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The company had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. The firm’s revenue for the quarter was down .1% compared to the same quarter last year. On average, equities analysts anticipate that AngioDynamics will post -0.41 EPS for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.